Rexahn Pharmaceuticals, a clinical-stage pharmaceutical company commercializing oncology and CNS therapeutics, said Dr. Chang Ahn has decided to transition his role as chief executive officer to chief science officer of Rexahn. He will continue to serve as chairman of Rexahn's board of directors.

Rexahn has initiated a search for a new CEO. Dr. Ahn will serve as both CEO and CSO until a new CEO is named to ensure a smooth transition.